After being voted down by an FDA panel last month, Sarepta Therapeutics Inc.'s (SRPT) Duchenne Muscular Dystrophy drug candidate Eteplirsen awaits the regulatory agency's final decision, which is set for May 26, 2016.
from RTT - Biotech http://ift.tt/1VhycF4
via IFTTT
No comments:
Post a Comment